Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2294-2301

  Lenaerts, Anne J ^a   Gruppo, Veronica ^a   Marietta, Karen S ^a   Johnson, Christine M ^a   Driscoll, Diane K ^a   Tompkins, Nicholas M ^a   Rose, Jerry D ^b   Reynolds, Robert C ^b   Orme, Ian M ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLODEXTRIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; METHYLCELLULOSE; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; NITROIMIDAZOPYRAN; PHOSPHATIDYLCHOLINE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 19544364888     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2294-2301.2005     Document Type: Article

References (27)

1. Agrawal, K. C., K. B. Bears, R. K. Sehgal, J. N. Brown, P. E. Rist, and W. D. Rupp. 1979. Potential radiosensitizing agents. Dinitroimidazoles. J. Med. Chem. 22:583-586.
2. Allen, B. W. 1998. Mycobacteria. General culture methodology and safety considerations. Methods Mol. Biol. 101:15-30.
3. Ashtekar, D. R., R. Costa-Perira, K. Nagrajan, N. Vishvanathan, A. D. Bhatt, and W. Rittel. 1993. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37:183-186.
4. Brennan, P. J. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 83:91-97.
5. Brooks, J. V., S. K. Furney, and I. M. Orme. 1999. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chcmother. 43:1285-1288.
6. Brooks, J. V., and I. M. Orme. 1998. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob. Agents Chemother. 42:3047-3048.
7. Choi, K. P., T. B. Bair, Y. M. Bae, and L. Daniels. 2001. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J. Bacteriol. 183:7058-7066.
8. Choi, K. P., N. Kendrick, and L. Daniels. 2002. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J. Bacteriol. 184:2420-2428.
9. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J. Exp. Med. 178:2243-2247.
10. Jacobs, M. R. 1999. Activity of quinolones against mycobacteria. Drugs 58(Suppl. 2):19-22.
11. Kelly, B. P., S. K. Furney, M. T. Jessen, and I. M. Orme. 1996. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2809-2812.
12. Konno, K., K. Oizumi, and S. Oka. 1973. Mode of action of rifampin on mycobacteria. II. Biosynthetic studies on the inhibition of ribonucleic acid polymerase of Mycobacterium bovis BCG by rifampin and uptake of rifampin-14 C by Mycobacterium phlei. Am. Rev. Respir. Dis. 107:1006-1012.
13. Lenaerts, A. J., V. Gruppe, J. V. Brooks, and I. M. Orme. 2003. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob. Agents Chemother. 47:783-785.
14. Mitchison, D. A. 2004. The search for new sterilizing anti-tuberculosis drugs. Front Biosci. 9:1059-1072.
15. Mitchison, D. A., and A. R. Coates. 2004. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr. Pharm. Design 10:3285-3295.
16. Murugasu-Oei, B., and T. Dick. 2000. Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J. Antimicrob. Chemother. 46:917-919.
17. Nagarajan, K., R. Gowrishankar, V. P. Arya, T. George, M. D. Nair, S. J. Shenoy, and V. Sudarsanam. 1992. Nitroimidazoles. Part XXIII. Activity of satranidazole series against anaerobic infections. Indian J. Exp. Biol. 30:193-200.
18. Orme, I. M. 2001. Search for new drugs for treatment of tuberculosis. Antimicrob. Agents Chemother. 45:1943-1946.
19. Schroeder, E. K., N. de Souza, D. S. Santos, J. S. Blanchard, and L. A. Basso. 2002. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 3:197-225.
20. Scior, T., I. Meneses Morales, S. J. Garces Eisele, D. Domeyer, and S. Laufer. 2002. Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis - a review. Arch. Pharm. (Weinheim) 335:511-525.
21. Stead, W. W. 1967. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am. Rev. Respir. Dis. 95:729-745.
22. Stover, C. K., P. Warrener, D. R. VanDevanter, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966.
23. Tead, W. W., G. R. Kerby, D. P. Schlueter, and C. W. Jordahl. 1968. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann. Intern. Med. 68:731-745.
24. Wallace, R. J., D. R. Nash, L. C. Steele, and V. Steingrube. 1986. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J. Clin. Microbiol. 24:976-981.
25. Walsh, J. S., R. Wang, E. Bagan, C. C. Wang, P. Wislocki, and G. T. Miwa. 1987. Structural alterations that differentially affect the mutagenic and anti-trichomonal activities of 5-nitroimidazoles. J. Med. Chem. 30:150-156.
26. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
27. World Health Organization. 2002. Controlling multi-drug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull. W. H. O. 80:489-501.